RHHVF - Roche Joins Bandwagon To Challenge Novo Nordisk Eli Lilly For Weight Loss Drugs | Benzinga
Roche Holding AG (OTC: RHHBY) has agreed to acquire a privately held obesity company Carmot Therapeutics, seeking to challenge the dominance of weight-loss drugs from Novo Nordisk A/S (NYSE: NVO) and Eli Lilly And Co (NYSE: LLY).
Carmot’s R&D portfolio includes clinical-stage subcutaneous and oral incretins to treat obesity in patients with and without diabetes and several preclinical programs, including:
- Injected subcutaneously once a week, CT-388, the lead asset, is a Phase-2 ready, dual GLP-1/GIP receptor agonist for obesity in patients with and without type 2 diabetes.
- CT-996, a once-daily oral, small molecule ...